The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Featured:
Your opinion matters
How challenging is it for you to achieve both clinically meaningful spleen volume reduction and constitutional symptom improvement in patients with cytopenic myelofibrosis?
During the 63rd ASH Annual Meeting and Exposition, the MPN Hub was pleased to speak to John Mascarenhas, Icahn School of Medicine at Mount Sinai, New York, US. We asked, How effective is pacritinib in managing symptoms and splenomegaly in cytopenic patients with myelofibrosis (MF)?
How effective is pacritinib in managing symptoms and splenomegaly in cytopenic patients with MF?
In this video, Mascarenhas discusses the analysis from the PERSIST-2 trial (NCT02055781), a randomized phase III study that investigated the safety and efficacy of oral pacritinib compared to the best available therapy to treat MF with thrombocytopenia.
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?